INTRODUCTION
Timely primary percutaneous coronary intervention (PPCI) with balloon dilatation and stent implantation is the standard treatment for patients with ST-segment elevation myocardial infarction (STEMI) [1, 2] . However, a patent infarct related artery does not necessarily translate into a good myocardial perfusion. In spite of PPCI, some patients still develop reduced coronary blood flow, despite a patent epicardial vessel, a complication thatis associated with impaired prognosis [3, 4] . An alternative strategy of delaying or deferring stent implantation, after a stable blood flow has been secured in the infarct-related artery, could preserve coronary blood flow and reduce the risk of embolization, and thereby potentially improve clinical outcome [5] [6] [7] [8] [9] . We report a case of deferred stenting in a patient presented with inferior wall ST-segment elevation myocardial infarction (IWMI).
Case Report
A 52-years old male patient presented to the emergency department (ED) with complaining of continuous chest pain for 10 hours and giddiness for 4 hours. The patient had been in his usual health, until approximately 8:30 on the morning of admission, when he developed suddenonset severe chest pain at rest. The pain was retrosternal, was crushing type, and was associated with profuse sweating. The pain did not worsen with inspiration and was associated with shortness of breath. Prior history was not significant for the related risk factors as hypertension, diabetes, dyslipidemia, family history of MI; except he was smoking excessively for a long duration. On physical examination, cardiac sounds were normal on auscultation. His blood pressure was 100/60mm Hg and heart rate was 40 bpm.Initial ECG showed complete heart block (CHB) with ST-segment elevation (STE) in leads II, III, AVF and V4R and ventricular escape rhythm of 40 for a minute (Fig 1) .
ECG showing complete heart block (chb) at presentation (a), paced rhythm after inserting tpi(b), normal sinus rhythm five days after index procedure Posterior wall ECG did not show any significant findings.
Transthoracic echocardiography (TTE) revealed hypokinesia of the inferior wall with a left ventricular ejection fraction (EF) of 50% and there was no intracardiac thrombosis, VSD or MR.
Before catheterization, the patient received a loading dose of aspirin 325 mg oral, prasugrel 60 mg oral and atorvastatin 80 mg oral. After due consent taken from patient, he was immediately taken to the catheterization laboratory. Temporary pacing wire was insertedand placed at a rate of 60 bpm. Coronary angiogram was performed at the same time. Coronary angiography revealed that the right coronary artery (RCA) was acutely and totally occluded at the mid-portion. Left system injection showedmid-70% segmental stenosis in the left anterior descending artery (LAD). There was milddisease of the left circumflex artery (LCX) which was a non-dominant vessel. We planned adhoc PTCA to culprit vessel. RCA mid occlusion was crossed by a floppy guidewire and serial pre-dilatation was performed with a short semi-compliant balloon. Thrombectomy of late has been proven no benefit, (though initial trials like TAPAS showed some promise, however the largest and latest registry total showed no decrease in infarct size and mortality; however an increase in stroke incidence was noted) [17] [18] [19] . Even thoughadditional intracoronary administration of adenosine resulted in a significant improvement of MVO during PPCI in REOPEN-AMI study; larger trials are needed to justify it [20] . Hence, DS can be considered as a better option in such kind of lesions.
DEFERRED STENTING STRATEGY
Deferred stenting (DS) reduces the risk of 'no-reflow' and increases myocardial salvage compared with immediate stenting [21] [22] [23] [24] [25] . Maximum stent diameter and length are both larger, indicating that the vessel dimensions will increase, likely due to attenuation of coronary artery tone with time from reperfusion [26] . However, the deferred strategy presents enormous issues in terms of cost and potential bleeding risk. Although prolonged GP IIb/IIIa use plays some role in dissolving thrombus, on the contrary, the extra antithrombotic therapy is negative because invariably it leads to increased bleeding. Another safety concern around DS is theoretical time related risk of coronary reocclusion and its consequences.Even social issues of a patient having negative outcomes despite a procedure being done are difficult to tackle practically especially in young patients. It is wise to have allow threshold for use of IABP in DS as it helps to maintain optimal perfusion to infracted area and also gives therapeutic safety edge in case emergency intervention needed [27] .In conclusion, DS strategy is double edged sword with the possibly lesser risk of no reflow, however at the expense of risk of re-occlusion, which could be life threatening in certain scenarios.
HEAD TO HEAD TRAILS
Registry data suggest that DS could preserve coronary blood flow and reduce the risk of embolization, and thereby potentially improve clinical outcome [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] . In a pilot study by Kelbaek H et al., DS reduced thrombus burden and increased myocardial salvage in patients with STEMI [38]. DS had fewer major cardiac events at 6 months compared to IS in a study by Tang et al [19] . In a meta-analysis, Freixa and colleagues concluded trend towards improved angiographic outcome in patients treated with DS [39] . DS did not reduce the occurrence of death, heart failure, myocardial infarction, or repeat revascularization compared with IS in DANAMI 3-DEFER study [40] . The major limitation of this study is that the trial did not select patients who were at the highest risk for developing MVO. In the majority of previous studies, untoward ischemic events and significant bleeding are infrequent in the interval between index reperfusion and actual stent implantation [21] [22] [23] [24] [25] .
Fewer patients in the deferred stenting group had no-/slow-reflow, no reflow and intra-procedural thrombotic events in DEFER STEMI study [41] . TIMI flow grades at the end of PCI were higher in the DS group. IS technique used in DEFER STEMI may have increased MVO because high rates of pre and post-dilatation were used compared with DS (57.7% versus 71.4%). Such balloon dilatation is necessary to avoid stent under expansion. But additional balloon dilatation may also increase the risk of MVO through distal embolization of thrombotic material. This might have had a confounding effect to explain the higher rate of angiographic slow-reflow in the IS group in this study. DS did not significantly reduce infarct size and the incidence of MVO compared with IS in INNOVATION study [42] . Paradoxically, there was a non-significant trend toward lower microvascular obstruction in IS group compared with DS group in The MIMI Study [43] . Again, no difference in 6-month outcomes was apparent for the rate of major cardiovascular and cerebral events in above study. These results completely rebut the promising findings of preliminary studies that suggested deferred stenting should translate to clinical benefit. In-fact MVO is not exclusive to immediate stenting group, defer stent group withpre-dilation or thrombosuction are also likely to have distal embolization. Hence, better solution theoretically for this problem is meshed stents (MGUARD), which trap the thrombotic muck, though 1 ST generation of these stents didn't show any benefit over routine DES, however results with 2 nd generation meshed stents are awaited and they hold a promise for future [44] . DS is therefore selectively advocated in subset of patients who are at increased risk of MVO such as increased age (i.e., 65 years of age or older), duration of symptoms > 6 h; heavy thrombus burden (TIMI grade 2 or higher), long lesion length (>24 mm), small vessel diameter (i.e., <2.5 mm), and clinical signs of acute microvascular injury after initial reperfusion with persistent ST-segment elevation >50% [25] [26] [27] [28] [29] . Is preferred over DS when the patient has cardiogenic shock, STEMI with Killip class III-IV or presenting as ventricular fibrillation, or sustained ventricular tachycardia and RVMI because the prognosis is very bad with these cases. STEMI patients with poor distal TIMI flow (0/1) despite adequate Predilatation and thrombosuction are also ideal candidates for DS because stenting with no distal runoff is dangerous and is a nidus for acute stent thrombosis. This is one such scenario where even BMS may be preferred over DES if at all we suspect vessel recoil to scaffold the vessel. Special subsets like young smokers with single vessel disease with less than 50% lesion after thrombosuction and those patients with residual lesions with negative FFR after thrombosuction and Predilatation may not need immediate stenting even though they are at low risk for MVO. STEMI patients with LM disease with low SYNTAX score will benefit from IS although those with high SYNTAX score may be left with no stenting and should be sent for emergency CABG.TVD cases with high SYNTAX score may benefit from deferring strategy, because long term PCI outcomes are poor compared to surgery and immediate priority is to restore flow in culprit artery(even in this scenario giving a waiting period of few minutes and checking for reclosure of vessel after wire is also removed may be helpful to assess behaviour of vessel and predict complications).However such patients have to be considered for early surgery. DS should not be adopted whenever there is coronary dissection following reperfusion, cardiac conditions requiring emergent or urgent surgical repair, failed thrombolysis and rescue PCI, and high risk of bleeding.
WHAT WE DID
As the patient presented late (approximately 10 hours) and RCA having a huge burden of thrombus despite thrombectomy, repeat coronary angiography with the intention to implant a stent in RCA (deferred strategy) was scheduled about 36 hours later. We came out with minimalist immediate mechanical intervention (MIMI). The patient was given an intravenous glycoprotein IIb/IIIa inhibitor (24 h infusion with Tirofiban). He also received intravenous high molecular weight heparin (UFH 60 U/kg every 6 h) for 36 hours. After 36 hours, he was again taken to the catheterization laboratory. A 7-French Judkins right (JR) 3.5 guide catheter (Cordis) was inserted through right common femoral access. Right coronary injection demonstrated decreased thrombus burden with residual 70% stenosis. ChoICE Floppy (Boston Scientific) guide-wire was used to navigate through the index lesion. The lesion was Predicated with 1.25 x 16 mm Sprinter® Legend semicompliant balloon (Medtronic, Inc.) followed by 2 x 10 mm balloon. We took a 2.75 x 28 mm Youkon Choice (Translumina Therapeutics LLP) drug-eluting stent and deployed it at 10 atmospheres (atm). After completion of the procedure, angiographic appearance of the stent was excellent, with the restoration of TIMI-3 flow (Fig3). The patient had normal sinus rhythm on 5 th day of index procedure. 
CONCLUSION
Deferring stenting in acute MI cannot be considered cardioprotective strategy, however, can be considered in selected group to lower the routine anticipated complications in primary interventions. More studies in larger subset of patients rather than single case report will be beneficial in drawing major conclusions and in formulating general practice guidelines in such cases. 
